Terms: = Ovarian cancer AND NBN, AT-V2, 4683, ENSG00000104320, ATV, FLJ10155, NBS, AT-V1, MGC87362, NBS1 AND Treatment
24 results:
1. Suppression of nbs1 Upregulates CyclinB to Induce Olaparib Sensitivity in ovarian cancer.
Zhong A; Cheng CS; Lu RQ; Guo L
Technol Cancer Res Treat; 2024; 23():15330338231212085. PubMed ID: 38192153
[No Abstract] [Full Text] [Related]
2.
Ramos CRN; Oliveira RJS; Rosa MN; Pereira AS; de Abreu RBV; van Helvoort Lengert A; Reis RM; Silva VAO; Palmero EI; Melendez ME
Curr Cancer Drug Targets; 2023; 23(11):900-909. PubMed ID: 37076963
[TBL] [Abstract] [Full Text] [Related]
3. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V
Cell Death Dis; 2022 Oct; 13(10):909. PubMed ID: 36307400
[TBL] [Abstract] [Full Text] [Related]
4. Moderate-Risk Genes for Hereditary ovarian cancers Involved in the Homologous Recombination Repair Pathway.
Abe A; Imoto I; Ueki A; Nomura H; Kanao H
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233090
[TBL] [Abstract] [Full Text] [Related]
5. Pancreatic cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract] [Full Text] [Related]
6. Homologous Recombination Deficiency: cancer Predispositions and treatment Implications.
Toh M; Ngeow J
Oncologist; 2021 Sep; 26(9):e1526-e1537. PubMed ID: 34021944
[TBL] [Abstract] [Full Text] [Related]
7. Iridium(III) Complex-Loaded Perfluoropropane Nanobubbles for Enhanced Sonodynamic Therapy.
Nittayacharn P; Abenojar E; La Deda M; Ricciardi L; Strangi G; Exner AA
Bioconjug Chem; 2022 Jun; 33(6):1057-1068. PubMed ID: 33677967
[TBL] [Abstract] [Full Text] [Related]
8. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
9. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
10. Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in cancer.
Wu Z; Li S; Tang X; Wang Y; Guo W; Cao G; Chen K; Zhang M; Guan M; Yang D
Theranostics; 2020; 10(9):3939-3951. PubMed ID: 32226530
[No Abstract] [Full Text] [Related]
11. DNA repair functional analyses of nbn hypomorphic variants associated with nbn-related infertility.
Fiévet A; Bellanger D; Zahed L; Burglen L; Derrien AC; Dubois d'Enghien C; Lespinasse J; Parfait B; Pedespan JM; Rieunier G; Stoppa-Lyonnet D; Stern MH
Hum Mutat; 2020 Mar; 41(3):608-618. PubMed ID: 31729086
[TBL] [Abstract] [Full Text] [Related]
12. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH
Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310
[TBL] [Abstract] [Full Text] [Related]
13. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
[TBL] [Abstract] [Full Text] [Related]
14. Genetic Predisposition to Breast cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract] [Full Text] [Related]
15. Network based stratification of major cancers by integrating somatic mutation and gene expression data.
He Z; Zhang J; Yuan X; Liu Z; Liu B; Tuo S; Liu Y
PLoS One; 2017; 12(5):e0177662. PubMed ID: 28520777
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological values of nbs1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract] [Full Text] [Related]
17. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
Koppensteiner R; Samartzis EP; Noske A; von Teichman A; Dedes I; Gwerder M; Imesch P; Ikenberg K; Moch H; Fink D; Stucki M; Dedes KJ
PLoS One; 2014; 9(6):e100041. PubMed ID: 24927325
[TBL] [Abstract] [Full Text] [Related]
18. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
Ziebarth AJ; Nowsheen S; Steg AD; Shah MM; Katre AA; Dobbin ZC; Han HD; Lopez-Berestein G; Sood AK; Conner M; Yang ES; Landen CN
Clin Cancer Res; 2013 Jan; 19(1):170-82. PubMed ID: 23147994
[TBL] [Abstract] [Full Text] [Related]
19. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy.
Abuzeid WM; Jiang X; Shi G; Wang H; Paulson D; Araki K; Jungreis D; Carney J; O'Malley BW; Li D
J Clin Invest; 2009 Jul; 119(7):1974-85. PubMed ID: 19487811
[TBL] [Abstract] [Full Text] [Related]
20. Microwave hepatic ablation: initial experience of safety and efficacy.
Martin RC; Scoggins CR; McMasters KM
J Surg Oncol; 2007 Nov; 96(6):481-6. PubMed ID: 17654527
[TBL] [Abstract] [Full Text] [Related]
[Next]
